Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | FPR1 | P21462 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 9/20 | 0.41 |
| ▸ | DHPS | P49366 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1833077 | 0.90 | ADRB2 (0.51) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1833669 | 0.82 | GPBAR1 (0.79) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1835081 | 0.81 | GPBAR1 (0.54) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1834627 | 0.81 | GPBAR1 (0.54) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1835389 | 0.79 | GPBAR1 (0.63) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1833747 | 0.78 | GPBAR1 (0.51) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL6795620 | 0.78 | GPBAR1 (0.45) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1832842 | 0.74 | ADRB2 (0.52) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1833921 | 0.74 | ADRB2 (0.75) | GPBAR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL1836114 | 0.74 | ADRB2 (0.68) | GPBAR1ADRB2FPR1GPR183APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281435-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-10-24 | — | — | US | disclosed |
| US-20110136788-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2322222-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Takeda Pharmaceutical Company Limited (JP) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136788-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | GPBAR1, GPR35, GRPR | GPBAR1 1/4885ADRB2 173/4885FPR1 363/4885 |
| US-20130281435-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | GPBAR1, GPR35, GRPR | GPBAR1 1/4885ADRB2 187/4885FPR1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.